Information Notice 2002-17, Attachment: Recent Misadministrations Caused by Incorrect Calibrations of STRONTIUM-90 Eye Applicators
| ML021630421 | |
| Person / Time | |
|---|---|
| Issue date: | 05/30/2002 |
| From: | Cool D NRC/NMSS/IMNS |
| To: | |
| Ayres R | |
| Shared Package | |
| ML021570590 | List: |
| References | |
| IN-96-066 IN-02-017 | |
| Download: ML021630421 (5) | |
Attachment 1 IN 02-17 UNITED STATES
NUCLEAR REGULATORY COMMISSION
OFFICE OF NUCLEAR MATERIAL SAFETY AND SAFEGUARDS
WASHINGTON, D.C. 20555 December 13, 1996 NRC INFORMATION NOTICE 96-66: RECENT MISADMINISTRATIONS CAUSED BY INCORRECT
CALIBRATIONS OF STRONTIUM-90 EYE APPLICATORS
Addressees
All U.S. Nuclear Regulatory Commission Medical Use Licensees authorized to use strontium-90 (Sr-90)
eye applicators.
Purpose
The U.S. Nuclear Regulatory Commission (NRC) is issuing this information notice to alert addressees to
recent misadministrations caused by incorrect source strength determinations of Sr-90 eye applicators.
It is expected that recipients will review the information for applicability to their facilities and consider
actions, as appropriate, to avoid similar problems. However, suggestions contained in this information
notice are not NRC requirements; therefore, no specific action nor written response is required.
Description of Circumstances
The primary causes of two recent events have been problems with calibration and calculation of the
dose rates from Sr-90 applicators. As a result, the administered doses were not within 20 percent of the
prescribed dose.
Case 1. In October 1995, during an inspection of a licensee authorized to use a Sr-90 eye applicator in
Mayagüez, Puerto Rico, it was determined that the calibration record for the licensee's Sr-90 eye
applicator was missing. A previous owner of the source lost the original calibration certificate, and his
medical physics consultant performed a check of the source strength. This check was performed with
an inappropriate measurement instrument and resulted in an incorrect determination of the source
strength as 0.24 Gray (Gy)/sec (24 rad/sec). The licensee obtained the source in 1994 and relied on the
erroneous source strength determination during treatments. Also, the source had not been
decay-corrected by either owner since 1990. NRC urged the licensee to have the eye applicator
recalibrated and to be instructed in the proper method to calculate the decay of the source.
The licensee subsequently had the eye applicator recalibrated by the National Institute of Standards and
Technology. The resultant recalibration revealed a dose rate of 0.53 Gray (53 rad)/sec rather than the
0.24 Gy (24 rad)/sec used by the licensee. The licensee had prescribed a total dose of between 10 to
25 Gy (1000 to 2500 rad) for approximately
9612090360
Attachment 1 IN 02-17 IN 96-66 December 13, 1996 70 patients, but actually administered about twice this amount. An NRC medical consultant has
reviewed the cases and has recommended that the patients be evaluated for any adverse effects.
Case 2. In November 1995, while reviewing treatment records during a routine NRC inspection of a
licensee authorized to use a Sr-90 eye applicator in Honolulu, Hawaii, an NRC inspector determined that
the licensee had incorrectly calculated the decay of the strength of a Sr-90 eye applicator and
subsequently delivered doses 20 percent over the prescribed doses to 16 patients.
The root cause of this event was the licensee improperly calculating the decay of the Sr-90 source.
Specifically, the licensee linearly decayed the strength of the source instead of logarithmically decaying
the source strength of the eye applicator. Before May 1995, a technologist had correctly calculated the
decay of the source; however, when this technologist left, the physician incorrectly calculated the source
decay based on a linear decay from the previous calculations. In addition, the incorrect half-life of Sr-90
was used in the calculation.
Following a correct determination of the source strength, the licensee determined that 17 misadministrations involving 16 patients occurred, from May 6, 1995 to November 16, 1995, including
one patient who was treated on both eyes. The delivered doses range from 21.1 to 22.7 percent greater
than the prescribed dose of 40 Gy (4000 rad).
Discussion
10 CFR 35.32, "Quality Management Program," requires licensees to develop written procedures to
meet five objectives associated with any brachytherapy dose, including assurance that the prescribed
dose is the administered dose. A necessary part of this is to ensure that the dose rate emitted from an
applicator is correct. If the manufacturers certificate of calibration or original activity/dose rate name
plate is missing, the licensee should arrange with a qualified expert to determine the dose rate from the
Sr-90 source. (For additional details, see NRC IN 94-17, "Sr-90 Eye Applicators: Submission of Quality
Management Plan, Calibration and Use," dated March 11, 1994.) Failure to implement the Quality
Management Rule and make required reports may subject a licensee to orders, civil penalties, and
notices of violation.
In view of the nature of the cited events, it appears worthwhile to review some of the properties of Sr-90
eye applicators and the related processes for decay correction over time. New Sr-90 eye applicators
typically contain a 2 gigabecquerel (GBq) [54 millicurie(mCi)] source, exhibiting a surface dose rate of
about 0.50 Gy (50 rad)/sec. The half-life of the parent Sr-90 is 28.5 yrs [maximum beta energy equal to
0.54 mega-electron volts (MeV)], and the yttrium-90 (Y-90) daughter half-life is 64.2 hrs (beta-max, 2.27 MeV); therefore, both isotopes are in equilibrium on the eye applicator. Since Sr-90 and Y-90 are in
equilibrium, emissions from both isotopes must be accounted for in dosimetry calculations.
Attachment 1 IN 02-17 IN 96-66 December 13, 1996 The dose rate (D. t) at a time (t) can be calculated from the initial dose rate (D. o) at the time of the most
recent calibration with the following formula:
D. t = D. o @ (e-t)
(F1)
where e, the base of the natural logarithm (2.718), is raised to the power -t and is referred to as the
"decay factor" (df), where - = -0.693/T1/2, T1/2 is the half-life of the isotope, and t is the elapsed time.
For Sr-90, T1/2=28.5 years; therefore, = (0.693)/(28.5 yrs) = 0.0243 yr-1. The values for df can be used
to determine the fraction of original activity remaining after t years. These values can then be used to
calculate dose rates by using the following formula:
D. t = D. o @ df
(F2)
The fraction of activity remaining after a given number of years from the original measurement date is
given in Table 1 (Attachment 1).
For example
An eye applicator calibrated by the manufacturer on January 1, 1978, delivered an initial dose rate ( D. o
) of 0.75 Gy/sec (75 rad/sec) on contact. If, on January 1, 1996, the eye applicator needs to be used, the
elapsed time (in years) since calibration is 18, and from Table 1, df = 0.646 for Sr-90.
Using formula F2:
D. t = D. o @ df
D. 18 years = (0.75 Gy/sec)(0.646)
D. 18 years = 0.485 Gy/sec (48.5 rad/sec)
Attachment 1 IN 02-17 IN 96-66 December 13, 1996 Table 1 may be extended using formula F1 and the value = 0.0243 yr-1 for Sr-90. Other values of df
that need to be evaluated by licensees will need to be re-calculated by using the appropriate half-life for
that isotope. Alternatively, a semi-logarithmic plot of the above data will yield a straight line, which may
be extended beyond 25 years.
This information notice requires no specific action nor written response. If you have any questions about
the information in this notice, please contact one of the technical contacts listed below or the appropriate
regional office.
signed by
Donald A. Cool, Director
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards
Technical contacts: Jose M. Diaz-Velez, RII
(404) 331-7438 Email: jxd2@nrc.gov
Emilio M. Garcia, RIV
(510) 975-0239 Email: emg@nrc.gov
James A. Smith, NMSS
(301) 415-7904 Email: jas4@nrc.gov
Attachments:
1. Table 1
Attachment 1